MONTREAL--(BUSINESS WIRE)--Mimetogen Pharmaceuticals Inc. today announced that it has appointed ophthalmic industry veteran Kim Brazzell, Ph.D. as Chief Medical Officer. Dr. Brazzell will lead the development of Mimetogen’s MIM-D3 pivotal program for the treatment of dry eye. The Company previously announced in June of 2011 that MIM-D3, a small molecule TrkA agonist, had successfully completed a 150-patient, multi-center Phase 2 trial for the treatment of dry eye, demonstrating significant improvements in signs and symptoms of the disease and an excellent safety profile.
